LUEbeck Registry of Intensive Care Patients - Characterization of the Patients Intestinal MICROBIOME
NCT ID: NCT04067271
Last Updated: 2022-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-03-18
2024-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
NCT05628493
Infection Surveillance in Intensive Care Patients
NCT00197847
Lung Microbiota Analysis in Critically Ill Patients Admitted to the Intensive Care Unit.
NCT04271345
The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?
NCT06749483
Alterations of the Microbiome During Critical Illness With Short and Long Term Clinical Outcomes
NCT04552834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Analyze changes in intestinal microbiome
Descriptive Analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients receiving intensive medical care
* A written informed consent from the patient or two independent doctors or legal guardians.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Luebeck
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. med. Tobias Graf
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Clinic II-UKSH Campus Lübeck
Lübeck, Schleswig-Holstein, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tobias Graf, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.